Three Reasons for Biopharmaceutical Labs to Add Mass Detection to Routine Analyses
As regulators focus in on the critical quality attributes of biotherapeutics, what can biopharmaceutical labs in late development or QC do to increase confidence in their bioseparations – other than to run more assays?